Hormonal IUD (Mirena/Kyleena) in Renal Impairment: What Women Need to Know

Why Renal Impairment Changes the Hormonal Picture

Chronic kidney disease (CKD) affects approximately 15% of U.S. Adults, and women with CKD face a specific set of reproductive and hormonal challenges that their male counterparts do not share. Menstrual irregularity, anovulation, and heavy uterine bleeding become more common as eGFR falls below 45 mL/min/1.73 m², partly because uremia disrupts the hypothalamic-pituitary-ovarian axis. A 2021 analysis published in the Clinical Journal of the American Society of Nephrology found that women with stage 3-5 CKD had significantly higher rates of abnormal uterine bleeding than age-matched controls, underscoring the relevance of intrauterine hormonal therapy in this population.

The levonorgestrel IUD sits at an interesting intersection here. It is both a contraceptive and a treatment for heavy menstrual bleeding, a condition that is already more common in CKD and that worsens anemia in women who are already prone to it. Understanding how impaired kidney function changes the drug's behavior is, therefore, clinically meaningful for any woman considering this device.

How CKD Alters Hormone Handling

Renal failure changes pharmacokinetics in several ways relevant to steroid hormones. These include reduced protein binding (because uremia lowers albumin and sex hormone-binding globulin, or SHBG), altered volume of distribution due to fluid retention, and impaired excretion of conjugated metabolites. SHBG is lower in women with advanced CKD, which means more circulating levonorgestrel is in its free, biologically active form. This could theoretically increase androgenic side effects, such as acne, hirsutism, or worsening of lipid profiles, even if total serum LNG levels appear modest.

Levonorgestrel itself is metabolized primarily in the liver via sulfation and glucuronidation, and its conjugates are excreted by both the kidneys and the bile. In women with severe renal impairment, some of these conjugates may accumulate. The clinical significance of this accumulation for a locally-acting intrauterine device is likely small, given that less than 20% of the dose from an IUD reaches the systemic circulation. But the absence of dedicated pharmacokinetic studies in women with eGFR <30 mL/min/1.73 m² is a real evidence gap (see more on this below).

The Fluid Retention Factor

Levonorgestrel has weak mineralocorticoid activity. In a woman with preserved renal function, this rarely matters. In a woman with stage 4-5 CKD or nephrotic syndrome, even mild sodium and water retention could tip the balance toward worsening edema, hypertension, or cardiovascular strain. This is not a reason to automatically avoid the device, but it is a reason to monitor blood pressure and fluid status closely in the first 3-6 months after insertion.

What the FDA Label Actually Says About Renal Impairment

The Mirena prescribing information states that formal pharmacokinetic studies in patients with renal impairment have not been conducted. The same is true for Kyleena's label. The practical guidance offered by both labels is silence on dose adjustment, which by convention means no adjustment is formally required. The Kyleena prescribing information similarly lists no renal-specific contraindication.

This is not reassuring in the way a well-powered pharmacokinetic trial would be. It means that clinicians are extrapolating from the drug's known hepatic clearance pathway and its low systemic bioavailability to conclude that renal impairment is unlikely to cause meaningful drug accumulation. That extrapolation is pharmacologically reasonable, but it is still an extrapolation.

What Counts as "No Dose Adjustment" for an IUD

For oral or injectable medications, "no dose adjustment needed" is a direct instruction. For an IUD, the concept is different. There is no titration dial. The device releases a fixed amount of levonorgestrel each day determined by its membrane and reservoir design. You cannot lower the dose if a patient experiences androgenic side effects; you can only remove the device or switch to the lower-dose Kyleena (19.5 mg total LNG vs. Mirena's 52 mg).

This is the practical titration question for renal-impaired women: start with Kyleena rather than Mirena if you are concerned about systemic exposure, particularly in women with nephrotic syndrome, advanced CKD, or significant hypoalbuminemia. Kyleena releases approximately 9 mcg/day of LNG initially, compared to Mirena's initial 20 mcg/day, and produces lower serum LNG concentrations overall.

Choosing Between Mirena and Kyleena in CKD: A Practical Framework

No published guideline specifically addresses which LNG-IUD formulation to prefer in women with CKD. The following framework draws on pharmacokinetic principles, the available label data, and clinical practice patterns described in nephrology-reproductive medicine literature.

Stage 1-2 CKD (eGFR 60-89 or 90+ with kidney damage markers): Either Mirena or Kyleena is appropriate. Monitor blood pressure at 3 and 6 months post-insertion. No special labs are required beyond your standard CKD monitoring panel.

Stage 3 CKD (eGFR 30-59 mL/min/1.73 m²): Both devices remain reasonable options. Consider Kyleena if the woman has signs of androgen excess (acne, hirsutism) or if SHBG is already low at baseline, since free LNG fraction may be higher. Check SHBG and albumin before insertion to contextualize any post-insertion side effects.

Stage 4-5 CKD (eGFR <30 mL/min/1.73 m²) and women on dialysis: Kyleena is the preferred starting device based on its lower total hormonal load. Some nephrologists prefer to coordinate insertion with a reproductive endocrinologist or urogynecologist experienced in CKD. Bleeding patterns should be tracked closely, as uremic platelet dysfunction may interact with LNG-related endometrial changes unpredictably. No prospective controlled trial has been done in this eGFR range, and shared decision-making should be explicit.

Kidney transplant recipients: This group warrants separate attention. Calcineurin inhibitors (tacrolimus, cyclosporine) are metabolized by CYP3A4, the same pathway that handles some LNG metabolism. The interaction evidence is limited. The CDC Medical Eligibility Criteria for Contraceptive Use (US MEC) classifies LNG-IUD use as MEC Category 2 for women who have had a solid organ transplant, meaning the benefits generally outweigh the risks. This is distinct from combined hormonal methods, which carry MEC Category 4 (unacceptable risk) in transplant recipients with vascular complications.

The SHBG-Free LNG Calculation: Why It Matters in CKD

In a healthy reproductive-age woman, roughly 47% of circulating LNG is bound to SHBG, 47% to albumin, and only 1-2% is free. In a woman with nephrotic-range proteinuria, SHBG can fall substantially, and albumin may be depleted. If both SHBG and albumin are low, the free LNG fraction could rise meaningfully. A serum SHBG below 30 nmol/L combined with albumin below 3.0 g/dL is a reasonable clinical trigger to consider Kyleena over Mirena, or to counsel the patient that androgenic side effects may be more prominent.

Life-Stage Considerations

Reproductive Years With CKD

Women of reproductive age with CKD need reliable contraception. Many are on medications that are teratogenic, including mycophenolate mofetil, ACE inhibitors, angiotensin receptor blockers, and certain immunosuppressants. For this group, highly effective, locally-acting contraception is especially important.

The LNG-IUD has over 99% typical-use effectiveness. It avoids the estrogen-related thrombotic risks of combined oral contraceptives, which matter in CKD patients who already have elevated cardiovascular risk. The American College of Obstetricians and Gynecologists (ACOG) has endorsed long-acting reversible contraception (LARC) as first-line for women seeking highly effective methods, and this recommendation applies with particular force when pregnancy itself carries maternal and fetal risk, as it often does in CKD.

Heavy menstrual bleeding is another reason to choose an LNG-IUD in reproductive-age women with CKD. Anemia is already prevalent in CKD due to reduced erythropoietin production. Adding iron-deficiency anemia from menorrhagia compounds the problem. A Cochrane review found that the 52 mg LNG-IUD reduced menstrual blood loss by approximately 90% at 3 months compared to baseline, a clinically meaningful reduction for a woman managing CKD-related anemia.

PCOS and CKD

Women with polycystic ovary syndrome (PCOS) have a higher prevalence of insulin resistance and metabolic syndrome, both of which are independent risk factors for CKD progression. If a woman has both PCOS and CKD, the LNG-IUD can address endometrial hyperplasia risk (elevated in PCOS due to unopposed estrogen from anovulation) while also reducing menstrual bleeding. Monitoring lipids after insertion is sensible, as LNG can modestly lower HDL cholesterol. In a woman whose lipids are already compromised by nephrotic syndrome or CKD-associated dyslipidemia, this additive effect is worth tracking.

Perimenopause and CKD

Perimenopausal women with CKD face a particular challenge. They may be starting systemic menopausal hormone therapy (MHT) with transdermal estradiol for vasomotor symptoms, and the LNG-IUD is an established method for providing the progestogen component of MHT while simultaneously protecting the endometrium. The Mirena 52 mg IUD is used off-label but widely in this context.

The ACOG Practice Bulletin on hormone therapy in menopause and guidance from The Menopause Society acknowledge the LNG-IUD as a reasonable progestogen delivery method in MHT regimens, though the FDA has not formally approved it for this indication in the U.S. In a perimenopausal woman with CKD, this approach has the advantage of minimizing systemic progestogen while still protecting the endometrium from unopposed estrogen.

Post-Menopause

In post-menopausal women, the LNG-IUD is not used for contraception. Its post-menopausal role is limited to the MHT context described above. Women with CKD stage 4-5 post-menopause who are not on MHT have little reason to use an LNG-IUD unless managing endometrial pathology specifically. This is a shared decision best made with both a gynecologist and a nephrologist.

Pregnancy and Lactation Safety

This section is required reading for any woman with CKD who is considering an LNG-IUD and may want to conceive.

Pregnancy

The levonorgestrel IUD is a contraceptive device. It is not intended to be used during pregnancy. If pregnancy occurs while the device is in place, the risk of ectopic pregnancy, spontaneous miscarriage, preterm delivery, and sepsis is elevated. The Mirena prescribing information states that the device should be removed if pregnancy is confirmed, and that removal itself carries a risk of pregnancy loss.

For women with CKD who wish to conceive, the device should be removed before attempting pregnancy. Fertility typically returns quickly after removal; ovulation can resume within the first month. Women with advanced CKD should discuss the timing of conception with both their nephrologist and obstetrician before removal, given that pregnancy in CKD stages 3b-5 carries significant maternal risks including accelerated renal decline, preeclampsia, and preterm birth.

Levonorgestrel is a progestogen with androgenic activity. Systemic progestogen exposure from the IUD is low enough that fetal virilization from inadvertent early pregnancy exposure has not been reported in registry data. The FDA does not assign traditional letter categories (A/B/C/D/X) under the current PLLR framework, but the general consensus is that continued intrauterine exposure is not desirable, and removal is always recommended when pregnancy is confirmed.

Lactation

Levonorgestrel IUDs are considered compatible with breastfeeding. LNG transfer into breast milk is low, with infant exposure estimated at less than 0.1% of the weight-adjusted maternal dose. No adverse effects on infant development have been documented in studies up to 12 months post-insertion. The CDC US MEC classifies LNG-IUD use in the postpartum period as MEC Category 1 (no restriction) after 4 weeks postpartum, and MEC Category 2 between birth and 4 weeks.

For a woman with CKD who is postpartum and breastfeeding, the LNG-IUD is often the preferred contraceptive choice precisely because it avoids estrogen, which carries thrombotic risk in the postpartum period on top of CKD-related vascular changes.

Contraception Counseling in Teratogenic Drug Co-Administration

Women with CKD are frequently prescribed mycophenolate mofetil (CellCept), which carries an FDA Boxed Warning for teratogenicity and requires two forms of contraception. The LNG-IUD counts as one effective method. A second method (such as a barrier method) is still required per the manufacturer's risk mitigation strategy when mycophenolate is used, even with an IUD in place. This is because the teratogenic risk is severe enough that the manufacturer and FDA require redundancy. Women on mycophenolate should not rely on the IUD alone.

ACE inhibitors and angiotensin receptor blockers, commonly used in CKD for renoprotection, are also contraindicated in pregnancy (FDA PLLR: fetal renal toxicity). The LNG-IUD provides excellent protection against unintended pregnancy while these agents are continued.

Monitoring Protocol for Women With CKD Using an LNG-IUD

Standard post-insertion follow-up typically occurs at 4-6 weeks. For women with CKD, a more structured monitoring schedule is reasonable.

At 4-6 weeks post-insertion: Check blood pressure and ask about edema. Confirm the device string is in place by pelvic exam or ultrasound. Review any bleeding pattern changes.

At 3 months: Repeat blood pressure. If SHBG was low at baseline, consider rechecking along with albumin. Note any new androgenic symptoms (acne, hair changes). Track menstrual blood loss change from baseline, particularly if anemia was a concern.

At 6 months: Hemoglobin and hematocrit to document anemia response, if heavy bleeding was the indication. Lipid panel if baseline dyslipidemia was present. Blood pressure.

Annually: Continue standard CKD monitoring per your nephrology team. The IUD does not require kidney-function-specific monitoring beyond what CKD already demands, but integrating gynecologic and nephrology care improves outcomes.

Evidence Gaps and What Is Extrapolated vs. Directly Studied

Women have been historically underrepresented in pharmacokinetic trials, and women with CKD are even more underrepresented. A 2020 review in the American Journal of Kidney Diseases documented that women constitute only 33-41% of enrollment in major CKD trials, with essentially no subgroup analysis of hormonal contraception. The following represents what is directly studied vs. Extrapolated for LNG-IUDs in CKD:

Directly studied:

• LNG-IUD pharmacokinetics in healthy reproductive-age women with normal renal function
• Efficacy and bleeding pattern data in women with heavy menstrual bleeding (no CKD subgroup)
• Safety in women on dialysis (small case series and registry data only; no RCT)
• LNG breast milk transfer (multiple small studies in lactating women)

Extrapolated from general pharmacology:

• That hepatic metabolism dominates and renal impairment does not substantially increase systemic LNG
• That lower SHBG in CKD raises free LNG fraction and may increase androgenic side effects
• That Kyleena's lower systemic exposure makes it a safer starting point in advanced CKD
• That conjugated LNG metabolite accumulation in severe renal failure is unlikely to be clinically significant

The honest answer is that no prospective, controlled pharmacokinetic or safety trial has enrolled women specifically with eGFR <30 mL/min/1.73 m² to evaluate LNG-IUD behavior. Until that data exists, practice will continue to rest on pharmacological inference and clinical experience.

Who This Is Right For (and Not Right For), by Life Stage

Good candidates for LNG-IUD with CKD

• Reproductive-age women with CKD stages 1-3 who need reliable contraception and want to avoid estrogen
• Women on teratogenic medications (ACE inhibitors, ARBs, mycophenolate) who need highly effective pregnancy prevention
• Women with CKD and heavy menstrual bleeding, where reducing blood loss will improve anemia
• Postpartum women with CKD who are breastfeeding and need contraception from 4 weeks onward
• Perimenopausal women with CKD who are starting transdermal estrogen MHT and need endometrial protection

Situations that warrant extra caution or an alternative

• Women with CKD stage 4-5 and uncontrolled hypertension, where even mild fluid retention from LNG is a concern. Start with Kyleena. Coordinate with nephrology before insertion.
• Women with nephrotic syndrome and very low SHBG and albumin, where free LNG fraction may be high enough to produce androgenic side effects
• Women with a distorted uterine cavity (fibroids are more common in Black women, who also have higher CKD prevalence), where device placement may be technically difficult
• Women on mycophenolate who understand that the IUD alone does not meet the two-contraception requirement and must add a barrier method
• Kidney transplant recipients on calcineurin inhibitors: LNG-IUD is MEC Category 2 (benefits outweigh risks), but insertion should be coordinated between gynecology and transplant medicine

"The LNG-IUD is underused in women with chronic kidney disease. Clinicians worry about systemic hormonal effects, but the local delivery mechanism makes this one of the lowest systemic steroid exposures available for contraception or menstrual management. The conversation should start with SHBG and albumin, not end with 'we'll avoid hormones.'" Dr. Rachel Goldberg, MD, WomanRx Women's Health Editorial Board.

Insertion Considerations in Women With CKD

Insertion technique does not change based on renal function, but a few practical points apply.

Women with advanced CKD and uremic platelet dysfunction may experience more procedural bleeding at insertion. Using misoprostol for cervical priming is a consideration in nulliparous women or those with cervical stenosis, though evidence for routine misoprostol use in IUD insertion is mixed. A 2022 ACOG Practice Bulletin does not recommend routine misoprostol for IUD insertion in all patients, but individual clinical judgment applies.

Women on anticoagulation, which some CKD patients require, may have heavier insertion bleeding but are not contraindicated from IUD placement. The small amount of endometrial disruption at insertion is generally well-tolerated even in anticoagulated women.

Baseline pelvic ultrasound to document uterine size and cavity before insertion is reasonable in any woman with a history of abnormal uterine bleeding, uterine fibroids, or prior uterine surgery. This is particularly relevant in Black women with CKD, who have higher rates of both fibroids and CKD.

The device string should be checked by the clinician or by the patient monthly for the first 3 months and then periodically, as expulsion rates are slightly higher in women with heavy bleeding, a common feature of CKD-related menorrhagia.